Cancer vaccines: the next immunotherapy frontier

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Therapeutic cancer vaccines are emerging as a viable option for patients resistant to standard immunotherapies.
• Despite progress, cancer vaccines have not yet reached their full therapeutic potential in expanding cancer treatment options.

Purpose of the Study:

• To classify cancer vaccines based on antigen characteristics, tumor expression, and antigen-presenting cell (APC) colocalization.
• To propose a framework for categorizing vaccines into predefined (shared or personalized) and anonymous (ex vivo or in situ) types.
• To emphasize the critical need for robust immune monitoring in early-phase trials to guide vaccine development.

Main Methods:

• Classification of cancer vaccines based on antigen knowledge (known vs. unknown).
• Analysis of tumor antigen expression profiles.
• Assessment of antigen colocalization with antigen-presenting cells within the tumor microenvironment.

Main Results:

• Delineation of cancer vaccines into predefined categories: shared and personalized.
• Categorization of vaccines into anonymous types: ex vivo and in situ.
• Identification of distinct vaccine classes based on antigen-specific and tumor-specific characteristics.

Conclusions:

• A systematic classification of cancer vaccines can aid in understanding their mechanisms and potential applications.
• Accurate immune monitoring is essential for identifying promising vaccine candidates and understanding trial outcomes.
• Further development and strategic clinical trial design are necessary to fully realize the potential of therapeutic cancer vaccines in oncology.